1:56 PM
 | 
Jan 02, 2019
 |  BC Extra  |  Financial News

China's Antengene raises $120M series B round

Antengene Corp. (Shanghai, China) completed a $120 million series B round to fund development of its two lead cancer compounds, selinexor and ATG-008.

Boyu Capital and FountainVest led the round, with participation by Celgene Corp. (NASDAQ:CELG), WuXi Corporate Venture Fund, Taikang and existing investors Qiming Venture Partners...

Read the full 215 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >